2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N12483
    Catenulopyrizomicin A
    		Inhibitor
    Catenulopyrizomicin A has a thiazolyl pyridine moiety. Catenulopyrizomicin A can be isolated from the fermentation broth of rare actinomycete Catenuloplanes sp. Catenulopyrizomicin A has anti-Hepatitis B virus activity.
    Catenulopyrizomicin A
  • HY-181348
    HBV-IN-56
    		Inhibitor
    HBV-IN-56 is an orally active HBsAg production inhibitor. HBV-IN-56 inhibits HBsAg production both in vitro and in vivo. HBV-IN-56 can be used for the research of chronic hepatitis B virus infection.
    HBV-IN-56
  • HY-173278
    AIC263282
    		Inhibitor
    AIC263282 is a potent Hepatitis B Virus (HBV) capsid assembly modulator with an EC50 of 3.8 nM. AIC263282 shows an IC50 of 61 nM for hERG. AIC263282 exhibits activity against viral replication and hepatitis B surface antigen (HBsAG) on primary human hepatocytes.
    AIC263282
  • HY-14844
    Lagociclovir
    		Inhibitor
    Lagociclovir (FLG) is a nucleoside analogue that inhibits wild-type hepatitis B virus (HBV) replication in a human hepatoma cell line permanently expressing HBV.
    Lagociclovir
  • HY-107454R
    OSS_128167 (Standard)
    		Inhibitor
    OSS_128167 (Standard) is the analytical standard of OSS_128167 (HY-107454). This product is intended for research and analytical applications. OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC50s of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects.
    OSS_128167 (Standard)
  • HY-100029AR
    Bay 41-4109 racemate (Standard)
    		Inhibitor
    Bay 41-4109 (racemate) (Standard) is the analytical standard of Bay 41-4109 (racemate). This product is intended for research and analytical applications. BAY 41-4109 racemate is the racemate of BAY 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
    Bay 41-4109 racemate (Standard)
  • HY-B0150S3
    Nicotinamide-d3
    		Inhibitor
    Nicotinamide-d3 (Niacinamide-d3) is deuterium labeled Nicotinamide. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.
    Nicotinamide-d<sub>3</sub>
  • HY-109197R
    Vonafexor (Standard)
    		Inhibitor
    Vonafexor (Standard) is the analytical standard of Vonafexor (HY-109197). This product is intended for research and analytical applications. Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research.
    Vonafexor (Standard)
  • HY-N3609
    Coclauril
    		Inhibitor
    Coclauril is an inhibitor of HBV. Coclauril inhibits HBV replication in the human hepatoblastoma cell line with an EC50 of 7.6 μg/mL.
    Coclauril
  • HY-17426S1
    Famciclovir-d6
    		Inhibitor
    Famciclovir-d6 (BRL 42810-d6) is deuterium labeled Famciclovir. Famciclovir (BRL 42810) is an orally active nucleoside analogue. Famciclovir is an antiviral agent with potent activities against HBV, HSV and VZV. Famciclovir can be used for the research of herpesvirus infection.
    Famciclovir-d<sub>6</sub>
  • HY-179393
    HBV-IN-54
    		Inhibitor
    HBV-IN-54 is a selective and orally active HBV inhibitor. HBV-IN-54 exhibits anti-HBV activity in both HepAD38 cells (EC50 = 0.020 μM, CC50 > 100 μM) and HLCZ01 cells (EC50 = 0.024 μM, CC50 > 100 μM). HBV-IN-54 inhibits viral replication in vivo. HBV-IN-54 displays favorable physicochemical properties and high plasma stability. HBV-IN-54 can be used for research on Hepatitis B (HBV).
    HBV-IN-54
  • HY-117999
    BAY39-5493
    		Inhibitor
    BAY39-5493 is a non-nucleoside inhibitor that inhibits HBV replication. BAY39-5493 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY39-5493 against HBV in stably transfected HepG2.2.15 cells is 0.03 μM.
    BAY39-5493
  • HY-17426R
    Famciclovir (Standard)
    		Inhibitor
    Famciclovir (Standard) is the analytical standard of Famciclovir. This product is intended for research and analytical applications. Famciclovir (BRL 42810) is an orally active nucleoside analogue. Famciclovir is an antiviral agent with potent activities against HBV, HSV and VZV. Famciclovir can be used for the research of herpesvirus infection.
    Famciclovir (Standard)
  • HY-116607
    BAY38-7690
    		Inhibitor
    BAY38-7690 is a non-nucleoside inhibitor that inhibits HBV replication. BAY38-7690 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY38-7690 against HBV in stably transfected HepG2.2.15 cells is 0.15 μM.
    BAY38-7690
  • HY-126970R
    HBF-0259 (Standard)
    		Inhibitor
    HBF-0259 (Standard) is the analytical standard of HBF-0259. This product is intended for research and analytical applications. HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC50 of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis.
    HBF-0259 (Standard)
  • HY-N0699R
    Daphnoretin (Standard)
    		Inhibitor
    Daphnoretin (Dephnoretin; Thymelol) (Standard) is the analytical standard of Daphnoretin (HY-N0699). This product is used for research and analytical applications. Daphnoretin is a protein kinase C (PKC) activator that can inhibit the expression of hepatitis B virus (HBV) surface antigen (HBsAg) and has antiviral activity. Daphnoretin exerts its anti-tumor effect by inhibiting the activation of the PI3K/AKT signaling pathway, triggering the mitochondrial apoptosis pathway. Daphnoretin alleviates chondrocyte apoptosis and inflammatory responses by inhibiting endoplasmic reticulum stress and the activation of the NLRP3 inflammasome. Daphnoretin can regulate the differentiation and maturation of dendritic cells, by down-regulating the phosphorylation level of JNK, inhibiting its immune stimulating function, thereby playing a protective role in skin transplant rejection reactions.
    Daphnoretin (Standard)
  • HY-136111
    KR-26556
    		Inhibitor
    KR-26556 is a sulfonamide type hepatitis B virus (HBV) capsid assembly regulator. KR-26556 exhibits anti-HBV activity with an EC50 of 0.04 μM. KR-26556 has favorable safety characteristics. KR-26556 can be used for research on chronic hepatitis B.
    KR-26556
  • HY-109014R
    Tenofovir exalidex (Standard)
    		Inhibitor
    Tenofovir exalidex (Standard) is the analytical standard of Tenofovir exalidex. This product is intended for research and analytical applications. Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC50s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV.
    Tenofovir exalidex (Standard)
  • HY-117925
    Personalised postprandial-targeting
    		Inhibitor
    Personalised postprandial-targeting is a way to modulate water-heme interactions with activity against low-spin P450 complexes. Personalised postprandial-targeting is able to maintain the axial water ligands of CYP2C9 even in the presence of inhibitors. Personalised postprandial-targeting also allows the hydrogen atoms of the axial water ligands to be observed by EPR spectroscopy, providing insights into the enzyme active site.
    Personalised postprandial-targeting
  • HY-P99541
    Tuvirumab
    		Inhibitor ≥99%
    Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research.
    Tuvirumab
Cat. No. Product Name / Synonyms Application Reactivity